News

Under the deal, Pamplona will purchase all of the outstanding shares of Parexel for $88.10 per share in cash, representing a 27.9% premium to its closing stock price

The action was taken by the biotechnology company after consultation with the Independent Data Monitoring Committee (IDMC) and a review of the unblinded data of the trial dubbed

In newborns, GBS manifests as sepsis, pneumonia, and meningitis, with potentially fatal outcomes for some, and long-lasting neurological damage in 46 to 50 percent of those infected. “Because

Dementia with Lewy bodies is the second-leading form of progressive dementia and affects over 1 million people in the United States. Currently, there are no approved therapies for

The approval has been granted for Rixathon to be used in all indications of the reference medicine, MabThera. Novartis has received approval for Rixathon to treat non-Hodgkin's lymphoma

The FDA has also approved the PFS trade name of Symjepi. Symjepi provides two single dose syringes of epinephrine (adrenaline), which is considered the drug of choice for

The companies intend to complete the deal by the fourth quarter 2017, at which time SK Biotek will continue to manufacture the current portfolio of small molecule pharmaceutical

The new data also showed that two years of Cosentyx treatment resulted in rapid and sustained pain relief in patients with active PsA. Novartis says that the new

Immune sold certain of these Ceplene-related assets to Meda AB in 2012.  Immune intends, through its Immuno-Oncology subsidary, Cytovia, Inc. ('Cytovia') to undertake commercialization efforts in Europe, Asia